Bomben et al. (2018) have reported that six representative genes (AKT3, BCL2, BTK, CD79B, PIK3CD and SYK) through the analysis of a prediction model were correlated with a poor clinical response in MCL. Ferrero et al. (2019) confirmed mutations of KMT2D and disruption of TP53 had a significantly increased risk of progression and death by target resequencing and DNA profiling in MCL samples. The gene discussed is BCL2; the disease is mantle cell lymphoma.